April 2021, Drugs Monitor, Page 4

(01 April 2021) Peginterferon Lambda-1a- did not improve the symptoms

April 20, 2021

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial https://doi.org/10.1038/s41467-021-22177-1 NCT04331899- a randomized, single-blind, placebo-controlled trial in 120 outpatients with mild to moderate COVID-19 was conducted to determine whether a single, 180 mcg subcutaneous dose of… Continue reading "(01 April 2021) Peginterferon Lambda-1a- did not improve the symptoms"

(30 Mar 2021) Ivermectin- improved the clinical state even in the presence of comorbidities

April 7, 2021

IVERMECTIN REPROPOSING FOR COVID-19 TREATMENT OUTPATIENTS IN MILD STAGE IN PRIMARY HEALTH CARE CENTERS https://www.medrxiv.org/content/10.1101/2021.03.29.21254554v1 NCT04784481- A significant reduction in the symptom numbers was observed in the EG when the medical examination was performed from 5th to 9th days, after starting treatment… Continue reading "(30 Mar 2021) Ivermectin- improved the clinical state even in the presence of comorbidities"

(26 Mar 2021) TenofovirDF- may be an effective antiviral in the treatment of COVID-19

April 7, 2021

Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV) https://www.medrxiv.org/content/10.1101/2021.03.24.21252635v1 NCT04812496- 104 patients were included: 36 in the HCQ group and 68 in the TDF group. The unadjusted primary outcomes were: LOS (length of… Continue reading "(26 Mar 2021) TenofovirDF- may be an effective antiviral in the treatment of COVID-19"

(26 Mar 2021) Levamisole- significantly better chance of clinical status including cough and dyspnea

April 7, 2021

Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial https://doi.org/10.1186/s12879-021-05983-2 IRCT20190810044500N7- With 25 patients in each arm, 50 patients with COVID-19 were enrolled in the study. Most of the study… Continue reading "(26 Mar 2021) Levamisole- significantly better chance of clinical status including cough and dyspnea"

(25 Mar 2021) Colchicine- associated with reduced mortality and accelerated recovery in COVID-19 patients

April 7, 2021

Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study https://doi.org/10.1371/journal.pone.0248276 Amongst the 141 COVID-19 patients (118 [83.7%] hospitalized), 70 (50%) received colchicine. The 21-day crude cumulative mortality was 7.5% in the colchicine group and 28.5%… Continue reading "(25 Mar 2021) Colchicine- associated with reduced mortality and accelerated recovery in COVID-19 patients"

(25 Mar 2021) Remdesivir- was associated with faster clinical improvement

April 7, 2021

Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19 https://doi.org/10.1001/jamanetworkopen.2021.3071 Of 2483 consecutive admissions, 342 individuals received remdesivir, 184 of whom also received corticosteroids and 158 of whom received remdesivir alone. For these… Continue reading "(25 Mar 2021) Remdesivir- was associated with faster clinical improvement"

(24 Mar 2021) Remdesivir- 22.9 % required mechanical ventilation compared to 44.7 % in the control group

April 7, 2021

Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study https://doi.org/10.3346/jkms.2021.36.e83 A total of 86 severe COVID-19 patients were evaluated including 48 remdesivir-treated patients. Baseline characteristics were not significantly… Continue reading "(24 Mar 2021) Remdesivir- 22.9 % required mechanical ventilation compared to 44.7 % in the control group"

(23 Mar 2021) Mavrilimumab- 57% patients alive compared to 47% in the placebo group

April 7, 2021

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial https://doi.org/10.1016/S2665-9913(21)00070-9 NCT04399980, NCT04463004, and NCT04492514-Between May 28 and Sept 15, 2020, 40 patients were enrolled and randomly assigned to mavrilimumab (n=21)… Continue reading "(23 Mar 2021) Mavrilimumab- 57% patients alive compared to 47% in the placebo group"

(20 Mar 2021) Tocilizumab-

April 7, 2021

Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series https://doi.org/10.1177/08971900211002353 All patients on admission to intensive care units had severe COVID-19 with 56% requiring mechanical ventilation with a pre-tocilizumab median (IQR) Pao2: Fio2 of 84 (69… Continue reading "(20 Mar 2021) Tocilizumab-"

(19 Mar 2021) Hydroxychloroquine- did not influence the severity of COVID 19

April 7, 2021

Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study https://doi.org/10.18087/cardio.2021.2.n1548 Analysis for the whole group revealed a statistically significant increase in the time to normalization of body temperature from 4 to 7 days (by 3 days, p<0.001), and… Continue reading "(19 Mar 2021) Hydroxychloroquine- did not influence the severity of COVID 19"

Month: April 2021